Literature DB >> 32561415

Heterogeneity and vascular permeability of breast cancer brain metastases.

Maria V Babak1, Michael R Zalutsky2, Irina V Balyasnikova3.   

Abstract

Improvements in the diagnosis and treatment of systemic breast cancer have led to a prolongation in patient survival. Unfortunately, these advances are also associated with an increased incidence of brain metastases (BM), with the result that many patients succumb due to BM treatment failure. Intracranial delivery of many chemotherapeutic agents and other therapeutics is hindered by the presence of an impermeable blood-brain barrier (BBB) designed to protect the brain from harmful substances. The formation of BM compromises the integrity of the BBB, resulting in a highly heterogeneous blood-tumor barrier (BTB) with varying degrees of vascular permeability. Here, we discuss how blood vessels play an important role in the formation of brain micrometastases as well as in the transformation from poorly permeable BM to highly permeable BM. We then review the role of BTB vascular permeability in the diagnostics and the choice of treatment regimens for breast cancer brain metastases (BCBM) and discuss whether the vasculature of primary breast cancers can serve as a biomarker for BM. Specifically, we examine the association between the vascular permeability of BCBM and their accumulation of large molecules such as antibodies, which remains largely unexplored.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Blood-brain barrier; Brain metastasis; Breast cancer; Therapeutics; Vascular permeability

Mesh:

Year:  2020        PMID: 32561415      PMCID: PMC7429312          DOI: 10.1016/j.canlet.2020.06.012

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.

Authors:  Weijun Wang; Haiping He; Nagore I Marín-Ramos; Shan Zeng; Steven D Swenson; Hee-Yeon Cho; Jie Fu; Paul M Beringer; Josh Neman; Ligang Chen; Axel H Schönthal; Thomas C Chen
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

Review 2.  Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy.

Authors:  Anna Niwinska; Katarzyna Pogoda; Agnieszka Jagiello-Gruszfeld; Renata Duchnowska
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 3.  Treating Metastatic Brain Cancers With Stem Cells.

Authors:  Nadia Sadanandan; Alex Shear; Beverly Brooks; Madeline Saft; Dorothy Anne Galang Cabantan; Chase Kingsbury; Henry Zhang; Stefan Anthony; Zhen-Jie Wang; Felipe Esparza Salazar; Alma R Lezama Toledo; Germán Rivera Monroy; Joaquin Vega Gonzales-Portillo; Alexa Moscatello; Jea-Young Lee; Cesario V Borlongan
Journal:  Front Mol Neurosci       Date:  2021-11-24       Impact factor: 5.639

4.  Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers.

Authors:  Yutian Feng; Rebecca Meshaw; Darryl McDougald; Zhengyuan Zhou; Xiao-Guang Zhao; Stephen A Jannetti; Robert E Reiman; Erica Pippen; Robin Marjoram; Jeffrey L Schaal; Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 5.  Brain Microvascular Pericytes-More than Bystanders in Breast Cancer Brain Metastasis.

Authors:  Danyyl Ippolitov; Leanne Arreza; Maliha Nuzhat Munir; Sabine Hombach-Klonisch
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.